Article Text

Download PDFPDF

967 Inflammatory tumour microenvironment in CRC alters macrophage function through mesenchymal stromal cell PD-1/PD-L1 signalling
  1. Niamh Leonard1,
  2. Shania Corry2,
  3. Oliver Treacy3,
  4. Eileen Reidy3,
  5. Keara Redmond2,
  6. Hannah Egan3,
  7. Margaret Sheehan4,
  8. Aoife Canney5,
  9. Aisling Hogan3,
  10. Daniela Loessner6,
  11. Laurence Egan3,
  12. Sean Hynes3,
  13. Thomas Ritter3,
  14. Philip Dunne3 and
  15. Aideen E Ryan3
  1. 1Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Science, Galway, Ireland
  2. 2Queens University Belfast, Belfast, UK
  3. 3National University of Ireland, Galway, Galway, Ireland
  4. 4University Hospital Galway, Galway, Ireland
  5. 5Galway University Hospital, Galway, Ireland
  6. 6Monash University, Melbourne, VIC, Australia
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Colorectal cancer (CRC) is the 3rd leading cause of cancer related deaths worldwide despite recent improvement in treatment options. CRC patients with mesenchymal stromal cell (MSC) rich tumours (CMS4 subtype) have the lowest survival rates and show high levels of immunosuppression and treatment resistance. However, the role MSCs play in tumour promotion, in particular, their interaction with macrophages, which are the most abundant immune cell in CRC, is not fully understood.

Methods Bioinformatics analysis of 433 primary CRC tumours assessed by microarray was used to determine transcriptional changes in CMS4 changes. These transcriptional changes were then further investigated using complex 2D conditioning and co-culture systems in but mouse and human. Primary MSC were isolated from CRC patient tumours and expanded ex vivo. A 3D Gelatin methacrylate hydrogel model of CMS4 like tumours was developed. This 3D model combine HCT116 cancer cells, THP1 monocyte cell line and bone marrow derived MSC.

Results In stromal rich CMS4 tumours, we observed an enhanced TNF-α signalling signature. MSCs were conditioned with inflammatory tumour cells secretome (iTCS), and we observed an increased expression of PD-L1 and CD47 by both RNA-seq and flow cytometry. Analysis of primary CRC patient tumours revealed higher numbers of macrophages in the stromal compartment CRC. Conditioned MSCs were co-cultured with macrophages and reduced MHC-II and TNF-α expression, increased CD206 expression, and suppressed phagocytic function in macrophages was observed. Blocking PD-1, the receptors for PD-L1, on macrophages, restored macrophage phagocytosis levels in these cultures. Using the 3D CMS4 like model, we could show that addition of MSCs to the culture system increased the secretion of MIF, SerpinE1, IL-8, CXCL12 and CXCL1, increased the transcription of extracellular matrix remodelling genes while also increasing cancer cell expression of EGFR, supporting tumour growth and proliferation.

Conclusions These results show that tumour associated MSCs alter macrophage function and promote tumour immune evasion in 2D and 3D models. Using physiologically relevant models we show that stromal cells enhance cell surface and secreted immunomodulatory molecule expression in the tumour microenvironment. These findings and experimental models may suggest novel therapeutic targets for patients with MSC rich tumours and improve treatment stratification of patients for immunotherapy treatment.

Ethics Approval CRC patient samples were obtained from patients undergoing colon tumour resection at University Hospital Galway under an ethically approved protocol (Clinical Research Ethics Committee, Ref: C.A. 2074). Written informed consent was obtained from all patients prior to collection.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.